Cost Efficacy of α-Galactosidase A Enzyme Screening for Fabry Disease.

Published on Jan 1, 2019
· DOI :10.1016/J.MAYOCP.2018.08.009
Darrell B. Newman5
Estimated H-index: 5
(Mayo Clinic),
William R. Miranda14
Estimated H-index: 14
(Mayo Clinic)
+ 5 AuthorsMichael J. Ackerman144
Estimated H-index: 144
(Mayo Clinic)
Abstract The prevalence of Fabry disease (FD) in adult patients with suspected hypertrophic cardiomyopathy (HCM) has been reported between 0.3% and 4%. Fabry disease–specific therapy necessitates early diagnosis; however, the optimal screening strategy and cost efficacy of routine α-galactosidase A (α-gal A) vs comprehensive galactosidase alpha gene (GLA) testing remain poorly understood. We identified 1192 patients who underwent routine α-gal A screening between January 1, 2011, and December 31, 2017, for suspected HCM. Cost efficacy was explored using prevalence and cost estimates. Ten patients had reduced α-gal A enzyme activity, and 5 (3 women) were ultimately diagnosed with FD (prevalence estimate, 0.42%). An alternative cardiac diagnosis was made in 3 patients with mildly reduced enzyme activity. Two women with reduced borderline enzyme levels did not undergo confirmatory testing, but FD was not suspected. The number needed to screen to diagnose 1 patient with FD in a similar cohort is estimated at 238 (5 new cases per 1192 at-risk individuals) at a cost of approximately US $24,000 per diagnosis. We identified a 0.42% prevalence of FD using routine α-gal A screening in adult patients referred to a dedicated HCM center in the United States. Compared with more comprehensive genetic testing strategies, we identified a similar prevalence of FD at a lower cost per diagnosis.
📖 Papers frequently viewed together
1 Author (N O. Pichkur)
8 Authors (İlyas Okur, ..., Alev Hasanoglu)
21 Citations
29 Citations
#1Dana Doheny (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 14
#2Ram Srinivasan (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 2
Last. Robert J. Desnick (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 120
view all 6 authors...
Background Fabry Disease (FD), an X linked lysosomal storage disease due to pathogenic α-galactosidase A ( GLA ) mutations, results in two major subtypes, the early-onset Type 1 ‘Classic’ and the Type 2 ‘Later-Onset’ phenotypes. To identify previously unrecognised patients, investigators screened cardiac, renal and stroke clinics by enzyme assays. However, some screening studies did not perform confirmatory GLA mutation analyses, and many included recently recognised ‘benign/likely-benign’ varia...
40 CitationsSource
#1Martin S. Maron (Tufts Medical Center)H-Index: 70
#2Winnie Xin (Harvard University)H-Index: 14
Last. Barry J. Maron (Tufts Medical Center)H-Index: 169
view all 8 authors...
Abstract Background Fabry disease is an X-linked lysosomal storage disorder caused by the deficient activity of α-galactosidase A due to mutations in the GLA gene, which may be associated with increased left ventricular wall thickness and mimic the morphologic features of hypertrophic cardiomyopathy. Management strategies for these 2 diseases diverge, with Fabry disease–specific treatment utilizing recombinant α-galactosidase A enzyme replacement therapy. Methods We studied a prospectively assem...
18 CitationsSource
#1Albina Nowak (UZH: University of Zurich)H-Index: 15
#2Thomas P. MechtlerH-Index: 14
Last. David C. KasperH-Index: 22
view all 4 authors...
Abstract Background Fabry disease (FD) is a rare X-linked lysosomal storage disorder due to mutations in the α-galactosidase A gene ( GLA ) that result in absent or markedly reduce α-galactosidase A (α-GalA) enzymatic activity. As a result, the major glycosphingolipid substrates, globotriaosylceramide (Gb3) and globotriaosylsphingosine (LysoGb3) accumulate in plasma, urine and tissue lysosomes. In females, the diagnosis can be complicated by the fact that 40–50% of GLA -mutation confirmed hetero...
67 CitationsSource
Fabry disease is caused by mutations in the GLA gene and is characterized by a large genotypic and phenotypic spectrum. Missense mutations pose a special problem for graduating diagnosis and choosing a cost-effective therapy. Some mutants retain enzymatic activity, but are less stable than the wild type protein. These mutants can be stabilized by small molecules which are defined as pharmacological chaperones. The first chaperone to reach clinical trial is 1-deoxygalactonojirimycin, but others h...
14 CitationsSource
#1J. Martijn Bos (Mayo Clinic)H-Index: 32
#2Melissa L. Will (Mayo Clinic)H-Index: 26
Last. Michael J. Ackerman (Mayo Clinic)H-Index: 144
view all 6 authors...
Abstract Objectives To determine the prevalence and spectrum of mutations and genotype-phenotype relationships in the largest hypertrophic cardiomyopathy (HCM) cohort to date and to provide an easy, clinically applicable phenotype-derived score that provides a pretest probability for a positive HCM genetic test result. Patients and Methods Between April 1, 1997, and February 1, 2007, 1053 unrelated patients with the clinical diagnosis of HCM (60% male; mean ± SD age at diagnosis, 44.4±19 years) ...
94 CitationsSource
#1Lorenzo MonserratH-Index: 35
#2Juan Ramón Gimeno-Blanes (ISCIII: Carlos III Health Institute)H-Index: 14
Last. J. Egido (ISCIII: Carlos III Health Institute)H-Index: 20
view all 12 authors...
Objectives We aimed to study the prevalence of Fabry disease (FD) in patients with hypertrophic cardiomyopathy (HCM). Background There are limited and controversial data about the prevalence of FD in patients with HCM. Methods We screened the plasma α-galactosidase A activity from 508 unrelated patients with HCM (328 men, 180 women, ages 58 ± 16 years). Patients with low activity (0% to 30% of the normal control in men, and 0% to 50% in women) underwent genetic study of the GLA gene. Results We ...
203 CitationsSource
#1Peter Kotanko (University of Graz)H-Index: 29
#1Peter Kotanko (University of Graz)H-Index: 34
Last. Gere Sunder-PlassmannH-Index: 58
view all 21 authors...
ABSTRACT. Anderson-Fabry disease is possibly underdiagnosed in patients with end-stage renal disease. Nationwide screening was therefore undertaken for Anderson-Fabry disease among dialysis patients in Austria. Screening for α-galactosidase A (AGAL) deficiency was performed by a blood spot test. In patients with a positive screening test, AGAL activity in leukocytes was determined. Individuals with decreased leukocyte AGAL activity were subjected to mutation testing in the GLA gene. Fifty (90.9%...
153 CitationsSource
#1Shoichiro Nakao (Kadai: Kagoshima University)H-Index: 22
#2Chihaya Kodama (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 1
Last. Robert J. Desnick (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 120
view all 12 authors...
Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Background Fabry disease is an X-linked recessive lysosomal storage disease resulting from deficient α-galactosidase A (α-Gal A) activity. Renal failure is a major debilitating complication in classically affected males. To determine if this disorder is underdiagnosed in patients with end-stage renal disease (ESRD), the frequency of unrecognized males with Fabry disease on chronic hem...
348 CitationsSource
#1B Sachdev (St George's Hospital)H-Index: 11
#2T. TakenakaH-Index: 2
Last. Perry M. ElliottH-Index: 112
view all 7 authors...
Background— Although studies have suggested that “late-onset” hypertrophic cardiomyopathy (HCM) may be caused by sarcomeric protein gene mutations, the cause of HCM in the majority of patients is unknown. This study determined the prevalence of a potentially treatable cause of hypertrophy, Anderson-Fabry disease, in a HCM referral population. Methods and Results— Plasma α-galactosidase A (α-Gal) was measured in 79 men with HCM who were diagnosed at ≥40 years of age (52.9±7.7 years; range, 40–71 ...
451 CitationsSource
#1Rj DesnickH-Index: 1
557 Citations
Cited By3
#1G.V. BaydakovaH-Index: 1
#2A.A. IlyushkinaH-Index: 1
Last. E.Y. ZakharovaH-Index: 1
view all 7 authors...
Abstract Fabry disease (FD [MIM:301500]) is an X-linked lysosomal storage disorder caused by mutations in the GLA gene. Deficient activity of its product, lysosomal enzyme α-galactosidase A (α-Gal A), leads to excessive accumulation of glycosphingolipids in cells of multiple organs. The establishing of the diagnosis is challenge in female patients because of milder clinical manifestation and normal α-Gal A activity. The globotriaosylsphingosine (lysoGb3) is described as a more sensitive diagnost...
6 CitationsSource
#1Darrell B. Newman (Mayo Clinic)H-Index: 5
#2Michael J. Ackerman (Mayo Clinic)H-Index: 144
#1Sergey MoiseevH-Index: 14
Last. Victor FominH-Index: 7
view all 5 authors...